Skip to search formSkip to main contentSkip to account menu

INC280

Known as: INCB028060 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

capmatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study
2017
2017
P2.04-005 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
2016
2016
A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).
4074Background: Overexpression/activation of cMET occurs in 20‒48% of HCC, and predicts worse survival. Capmatinib (INC280) is a… 
2016
2016
MINI01.04: ROS1 Fusion Chinese Lung Adenocarcinoma Patients Treated with Crizotinib Detected Using Next‐Generation Genotyping from ctDNA: Topic: Medical Oncology
2015
2015
Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung.
2587 Background: MET dysregulation is one mechanism of EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor… 
2015
2015
Abstract 782: Modulation of receptor tyrosine kinase signaling by cMET inhibitor, INC280, in cMETmut/amp gastric carcinoma cell line Hs746.T
Aberrant Receptor Tyrosine Kinase (RTK) activity is one of the hallmarks of cancer. The genetic alternations of ABL and EGFR are… 
2014
2014
Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.
2520^ Background: Aberrations in the MET receptor tyrosine kinase pathway occur in various human malignancies (via MET… 
2014
2014
Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma
Epithelioid sarcoma (EpS) is a high-grade malignant soft-tissue sarcoma characterized by local recurrences and distant metastases… 
2013
2013
Abstract 2079: Antitumoral activity of INC280 against adult glioblastoma brain tumors xenografts.
INTRODUCTION: INC280 is an oral, highly selective c-Met receptor tyrosine kinase inhibitor. The hepatocyte growth factor (HGF)-c… 
2008
2008
Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment
2577 The Met receptor tyrosine kinase (RTK) is the only high-affinity receptor for the hepatocyte growth factor (HGF). Met kinase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)